Research & Markets: With Sales of Over US$4.6 Billion Sandoz is Currently the Second Largest Generic Manufacturer in the World

Business Wire, May 30, 2007

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c36147) has announced the addition of the Espicom Business Intelligence Ltd report: Sandoz Generics Company Intelligence Report to their offering.

Our generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.

Topics Covered

Executive Summary
Introduction
Canada
Products
Sandoz ANDA Approvals, 2002-06
Geneva Pharmaceuticals ANDA Approvals, 2002-03
Lek ANDA Approvals, 2002-03
Eon Labs ANDA Approvals, 2002-05
Recent product approvals
Sandoz
Omnitrope approved in EU and USA
EU
USA
US zonisamide approval
US cefprozil approval
US azithromycin approval
US leflunomide approval
US ceftriaxone injection launch announced
Australian TGA approves Omnitrope
Recent product approvals
Hexal
Tramadol (Labopharm)
Fentanyl patch
Financial results
Latest Yearly Results
Sandoz: 2005 results (US$ millions)
Latest Quarterly Results
Sandoz: third quarter 2006 results (US$ millions)
Sandoz: nine months 2006 results (US$ millions)
Major developments
Facilities
Pliva acquires Sandoz Spanish subsidiary
Lek opens new facility in Slovenia
Mergers, acquisitions and agreements
Momenta enters expanded collaboration agreement with Sandoz
Sandoz completes purchase of Hexal and Eon Labs
Novartis India plans to transfer facility to Sandoz
Sabex
Durascan
Amifarma
Lek acquisition
Litigation
Barr confirms warfarin settlement with Sandoz
Pfizer petitions the FDA to recall Tevas and Sandoz azithromycin
    products
AstraZeneca and Eon Labs in metoprolol patent litigation
Amoxicillin and clavulanate
Contact Details
Summary

Sandoz is a subsidiary of Novartis, now headquartered in Germany. The subsidiary was formerly a collection of companies under the Novartis Generics umbrella name, but a major rebranding and reorganisation process began in 2002.

Sandoz is currently the second largest generic manufacturer in the world, behind Teva, with sales of over US$4.6 billion in 2005. The company completed its acquisition of Hexal and Eon Labs in June 2005, in one of the generic industry's largest mergers. The combined company has a new HQ in Germany. Teva will retain the number one spot, however, through its recently-announced purchase of IVAX.

Major production sites are in Austria, the USA, Germany and Slovenia. Around two thirds of the company's workforce is based in Europe. The US subsidiary was formerly known as Geneva Pharmaceuticals, owned by Novartis since 1979. Novartis purchased the major Slovenian producer, Lek, in 2003. Lek has a major presence in the CEE region.

Sandoz is a frontrunner in the development of biosimilar products. Its human growth hormone product, Omnitrope, has received approval in Australia, the EU and the USA. It is already on the market in Germany, Austria and Australia, with more launches planned during the year.

Companies Mentioned

- Pliva
- Lek
- Momenta
- Sandoz
- Hexal
- Eon Labs
- Novartis
- Sabex
- Durascan
- Amifarma

For more information visit http://www.researchandmarkets.com/reports/c36147.>

COPYRIGHT 2008 Gale, Cengage Learning